Molecular Genetics of Malignant Mesothelioma


Malignant mesothelioma (MM) is an aggressive tumour arising primarily from the pleural or peritoneal cavities. MM develops by asbestos exposure after a long latency, which is highly refractory to conventional therapeutic modalities. Molecular genetic analysis has revealed several key genetic alterations which are responsible for the development and progression of MM. The frequently mutated tumour suppressor genes detected in MM cells are CDKN2A/ ARF, NF2, BAP1, and LATS2. In contrast, frequent activating mutation of any oncogenes has not been clearly identified yet, which is one of the reasons that current molecular target therapy is not very effective for MM patients. Recent studies have also indicated characteristic epigenetic alterations in MM, which include distinct deoxyribonucleic acid (DNA) methylation patterns and the involvement of noncoding ribonucleic acid (RNA). Aberrant histone modification caused by BAP1 inactivation may also lead to the disturbance of global expression profiling. With further comprehensive genome analyses, new genetic and epigenetic alterations in MM cells are expected to be revealed more precisely, and the new knowledge based on them would be applied for developing a new diagnostic tool and new target therapies against MMs.

Key Concepts:

  • Malignant mesothelioma cells harbour multiple key genetic mutations, which mainly inactivate tumour suppressor genes.

  • Asbestos fibre induces chromosome and DNA damages in normal mesothelial cells with several possible mechanisms, but it is not clear why it takes so long from asbestos exposure to mesothelioma development.

  • People differ in their susceptibility to development of mesothelioma after similar levels of asbestos exposure, possibly due to the differences in genetic polymorphisms or expression levels of genes involved in the DNA repair system and epigenetics modification.

  • Mesothelioma has long been considered a representative type of tumour primarily caused by environmental factors, especially asbestos, but familial cases of mesothelioma with a specific gene mutation have challenged this idea.

  • Neurofibromatosis type 2 (NF2) gene inactivation is found in a nearly half of mesothelioma cases and the inactivation of one of its downstream signal transduction cascades, Hippo signalling, plays a significant role in dysregulation of cell proliferation.

  • Epigenetic alterations such as aberrant histone modification by BAP1 gene inactivation play significant roles in mesothelioma development.

  • The overall picture of the genetic abnormality landscape of mesothelioma cells lags behind other common human malignancies.

  • If an oncogene‚Äźtype gene with frequent activating mutation in mesothelioma cells were discovered, molecular target strategies aiming at controlling the activated molecule could be aggressively pursued to develop new therapeutic tools against mesothelioma.

Keywords: malignant mesothelioma; genome; oncogene; tumour suppressor gene; CDKN2A; NF2; BAP1; epigenetics

Figure 1.

Possible mechanisms of asbestos‐induced carcinogenesis. Reproduced from Toyokuni with permission of Nagoya University School of Medicine/Graduate School of Medicine. Reproduced from “Mechanisms of asbestos‐induced carcinogenesis” by Toyokuni S (Nagoya J. Med. Sci. 71, p1‐10, 2009) with permission of Nagoya University School of Medicine/Graduate School of Medicine, with permission from Nagoya University School of Medicine.

Figure 2.

Schematic representation of Merlin (Mer)‐Hippo signalling cascade. Signals from extracellular environment, transduced via cell–cell contact (cadherin), cell‐matrix contact (CD44), or growth factors (RTKs), affect the tumour‐suppressive activity of Merlin. Activated (underphosphorylated) Merlin regulates the Hpo (Hippo) cascade, suppressing the activity of YAP transcriptional coactivator. Merlin also regulates mTOR signalling pathway in MM cells. SMAD2/3 activated by TGF‐β makes a complex with YAP and TEAD to transcribe CTGF. CTGF, connective tissue growth factor; LATS2, large tumour suppressor homologue 2; Mer, Merlin; MST, mammalian sterile 20‐like kinase; mTORC1, mammalian target of rapamycin; RTK, receptor tyrosine kinase; SAV1, Salvador homolog 1; TEAD, TEA domain family member; TGF, transforming growth factor; YAP, Yes‐associated protein.

Figure 3.

BAP1 tumour suppressor. (a) Schematic representation of BAP1. BAP1 is a 729 amino acid protein that functions as a nuclear‐localised deubiquitinating enzyme (DUB). BAP1 binds to multiple proteins including the transcriptional regulator (HCF‐1), and (ASXL1/2) and BRCA1. Human BAP1 is composed of a (UCH) domain (1‐240 a.a.), an (HBM) (NHNY, 363‐366 a.a.), a region that mediates association with BRCA1 (596‐721 a.a.), a helical motif that shares conservation with UCH family proteins (ULD for UCH37‐like domain, 634‐694), and a (NLS, 717‐722 a.a.). (b) Two major BAP1 deubiquitination targets, HCF‐1 and histone 2A, are involved in chromatin modification and transcriptional regulation. HDAC, histone deacetylase; HMT, histone methyl transferase; PRC, Polycomb complex; Ub, ubiquitin.



Altomare DA, Menges CW, Pei J et al. (2009) Activated TNF‐alpha/NF‐kappaB signaling via down‐regulation of Fas‐associated factor 1 in asbestos‐induced mesotheliomas from Arf knockout mice. Proceedings of the National Academy of Sciences of the USA 106: 3420–3425.

Altomare DA, Menges CW, Xu J et al. (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos‐induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One 6: e18828.

Altomare DA, Vaslet CA, Skele KL et al. (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Research 65: 8090–8095.

Below JE, Cox NJ, Fukagawa NK et al. (2011) Factors that impact susceptibility to fiber‐induced health effects. Journal of Toxicology and Environmental Health. Part B, Critical Reviews 14: 246–266.

Bianchi AB, Mitsunaga SI, Cheng JQ et al. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proceedings of the National Academy of Sciences of the USA 92: 10854–10858.

Bott M, Brevet M, Taylor BS et al. (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics 43: 668–672.

Busacca S, Germano S, De Cecco L et al. (2009) MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. American Journal of Respiratory Cell and Molecular Biology. Epub ahead of print.

Carbone M, Emri S, Dogan AU et al. (2007) A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nature Reviews Cancer 7: 147–154.

Christensen BC, Houseman EA, Godleski JJ et al. (2009) Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Research 69: 227–234.

Christensen BC, Houseman EA, Poage GM et al. (2010) Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Research 70: 5686–5694.

Donaldson K, Murphy FA, Duffin R et al. (2010) Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Particle and Fibre Toxicology 7: 5.

Eletr ZM and Wilkinson KD (2011) An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochemistry and Biophysics 60: 3–11.

Fischer JR, Ohnmacht U, Rieger N et al. (2006) Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54: 109–116.

Fujii M, Toyoda T, Nakanishi H et al. (2012) TGF‐beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. Journal of Experimental Medicine 209: 479–494.

Goto Y, Shinjo K, Kondo Y et al. (2009) Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Research 69: 9073–9082.

Guled M, Lahti L, Lindholm PM et al. (2009) CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma‐A miRNA microarray analysis. Genes, Chromosomes and Cancer 48: 615–623.

Harbour JW, Onken MD, Roberson ED et al. (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330: 1410–1413.

Hu Q, Akatsuka S, Yamashita Y et al. (2010) Homozygous deletion of CDKN2A/2B is a hallmark of iron‐induced high‐grade rat mesothelioma. Laboratory Investigation 90: 360–373.

Husain AN, Colby TV, Ordonez NG et al. (2009) Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine 133: 1317–1331.

Jakobsen JN and Sorensen JB (2011) Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemotherapy and Pharmacology 68: 1–15.

Jongsma J, van Montfort E, Vooijs M et al. (2008) A conditional mouse model for malignant mesothelioma. Cancer Cell 13: 261–271.

Li W, You L, Cooper J et al. (2010) Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140: 477–490.

Liu W, Ernst JD and Broaddus VC (2000) Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis in mesothelial cells. American Journal of Respiratory Cell and Molecular Biology 23: 371–378.

Mizuno T, Murakami H, Fujii M et al. (2012) YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle‐promoting genes. Oncogene. doi:10.1038/onc.2012.5 [Epub ahead of print].

Monaco SE, Shuai Y, Bansal M et al. (2011) The diagnostic utility of p16 FISH and GLUT‐1 immunohistochemical analysis in mesothelial proliferations. American Journal of Clinical Pathology 135: 619–627.

Murakami H, Mizuno T, Taniguchi T et al. (2011) LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Research 71: 873–883.

Musti M, Kettunen E, Dragonieri S et al. (2006) Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genetics and Cytogenetics 170: 9–15.

Nagai H, Okazaki Y, Chew SH et al. (2011) Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proceedings of the National Academy of Sciences of the USA 108: E1330–E1338.

Pan D (2010) The hippo signaling pathway in development and cancer. Developmental Cell 19: 491–505.

Pass HI, Goparaju C, Ivanov S et al. (2010) hsa‐miR‐29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Research 70: 1916–1924.

Pass HI, Vogelzang N, Hahn S et al. (2004) Malignant pleural mesothelioma. Current Problems in Cancer 28: 93–174.

Robinson BW and Lake RA (2005) Advances in malignant mesothelioma. New England Journal of Medicine 353: 1591–1603.

Roe OD, Anderssen E, Sandeck H et al. (2010) Malignant pleural mesothelioma: genome‐wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 67: 57–68.

Sekido Y, Pass HI, Bader S et al. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Research 55: 1227–1231.

Sugarbaker DJ, Richards WG, Gordon GJ et al. (2008) Transcriptome sequencing of malignant pleural mesothelioma tumors. Proceedings of the National Academy of Sciences of the USA 105: 3521–3526.

Taniguchi T, Karnan S, Fukui T et al. (2007) Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32. Cancer Science 98: 438–446.

Testa JR, Cheung M, Pei J et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics 43: 1022–1025.

Thurneysen C, Opitz I, Kurtz S et al. (2009) Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64: 140–147.

Toumpanakis D and Theocharis SE (2011) DNA repair systems in malignant mesothelioma. Cancer Letters 312: 143–149.

Toyokuni S (2009) Mechanisms of asbestos‐induced carcinogenesis. Nagoya Journal of Medical Science 71: 1–10.

Tsao AS, Wistuba I, Roth JA et al. (2009) Malignant pleural mesothelioma. Journal of Clinical Oncology 27: 2081–2090.

Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 21: 2636–2644.

Wiesner T, Obenauf AC, Murali R et al. (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics 43: 1018–1021.

Xio S, Li D, Vijg J et al. (1995) Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11: 511–515.

Yang H, Bocchetta M, Kroczynska B et al. (2006) TNF‐alpha inhibits asbestos‐induced cytotoxicity via a NF‐kappaB‐dependent pathway, a possible mechanism for asbestos‐induced oncogenesis. Proceedings of the National Academy of Sciences of the USA 103: 10397–10402.

Yokoyama T, Osada H, Murakami H et al. (2008) YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 29: 2139–2146.

Yoshikawa Y, Sato A, Tsujimura T et al. (2012) Frequent inactivation of BAP1 gene in epithelioid‐type malignant mesothelioma. Cancer Science 103: 868–874.

Further Reading

Goldstein AM (2011) Germline BAP1 mutations and tumor susceptibility. Nature Genetics 43: 925–926.

Heintz NH, Janssen‐Heininger YM and Mossman BT (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. American Journal of Respiratory Cell and Molecular Biology 42: 133–139.

Scherpereel A, Astoul P, Baas P et al. (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal 35: 479–495.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Sekido, Yoshitaka(Jul 2012) Molecular Genetics of Malignant Mesothelioma. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0022448]